This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

Background Despite the greater prevalence of familial hypercholesterolemia (FH) in
subjects with ischemic heart disease (IHD), premature IHD, and severe …

Although awareness of familial hypercholesterolemia (FH) is increasing, this common,
potentially fatal, treatable condition remains underdiagnosed. Despite FH being a genetic …

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary
heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and …

Familial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant
disorder that affects% 1 in 220 individuals globally. 1 FH is characterized by lifelong …

Abstract Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening
condition characterized by markedly elevated circulating levels of low-density lipoprotein …

Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

Importance Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated
genetic disorder that leads to premature morbidity and mortality due to atherosclerotic …

Background: Although risk factors for atherosclerotic cardiovascular disease (ASCVD) in
familial hypercholesterolemia (FH) have been described, models for predicting incident …

Aims Ideally, familial hypercholesterolaemia (FH) is diagnosed by testing for mutations that
decrease the catabolism of low-density lipoprotein (LDL) cholesterol; however, genetic …